





**THROMBECTOMIE : 2^{ème} REVOLUTION THERAPEUTIQUE DE
L'INFARCTUS CEREBRAL**
B. GORY, F. TURJMAN & F. COTTON
Samedi Matin 25 Juin 2016




L'IRM est-elle indispensable pour la thrombectomie ?

O. Naggar, W. Ben Hassen,
C.Rodriguez-Régent, G. Boulouis, D.Tystram,
D. Calvet, G. Turc, J-L. Mas,
C. Oppenheim, J-F. Meder



Pati^ente âgée de 58 ans, déficit neurologique brutal depuis 1h30. mutisme, déficit hémⁱ-corporel droit. NIHSS = 15



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JANUARY 1, 2015

VOL. 372 NO. 1

A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke

O.A. Berkhemer, P.S.S. Fransen, D. Beumer, L.A. van den Berg, H.F. Lingsma, A.J. Yoo, W.J. Schonewille, J.A. Vos, P.J. Nederkoorn, M.J.H. Warmer, M.A.A. van Walderveen, J. Staals, J. Hofmeijer, J.A. van Oostayen, G.J. Lycklama à Nijeholt, J. Boiten, P.A. Brouwer, B.J. Emmer, S.F. de Brujin, L.C. van Dijk, L.J. Kappelle, R.H. Lo, E.J. van Dijk, J. de Vries, P.L.M. de Kort, W.J.J. van Rooij, J.S.P. van den Berg, B.A.A.M. van Hasselt, L.A.M. Aerdien, R.J. Dallinga, M.C. Visser, J.C.J. Bot, P.C. Vroomen, O. Eshghi, T.H.C.M.L. Schreuder, R.J.J. Heijboer, K. Keizer, A.V. Tielbeek, H.M. den Hertog, D.G. Gerrits, R.M. van den Berg, Vos, G.B. Karas, E.W. Steyerberg, H.Z. Flach, H.A. Marquering, M.E.S. Sprengers, S.F.M. Jennikens, L.F.M. Beenken, R. van den Berg, P.J. Koudstaal, W.H. van Zwam, Y.B.W.E.M. Roos, A. van der Lugt, R.J. van Oostenbrugge, C.B.I.M. Majoor, and D.W.J. Dippel, for the MR CLEAN Investigators*

ABSTRACT

BACKGROUND

In patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion, intraarterial treatment is highly effective for emergency revascularization. However, proof of a beneficial effect on functional outcome is lacking.

METHODS

We randomly assigned eligible patients to either intraarterial treatment plus usual care or usual care alone. Eligible patients had a proximal arterial occlusion in the anterior cerebral circulation that was confirmed on vessel imaging and that could be treated intraarterially within 6 hours after symptom onset. The primary outcome was the modified Rankin score at 90 days; this categorical scale measures functional outcome, with scores ranging from 0 (no symptoms) to 6 (death). The treatment effect was estimated with ordinal logistic regression as a common odds ratio, adjusted for prespecified prognostic factors. The adjusted common odds ratio measured the likelihood that intraarterial treatment would lead to lower modified Rankin scores, as compared with usual care alone (shift analysis).

RESULTS

We enrolled 500 patients at 16 medical centers in the Netherlands (233 assigned to intraarterial treatment and 267 to usual care alone). The mean age was 65 years (range, 23 to 96), and 445 patients (89.0%) were treated with intravenous alteplase before randomization. Retrievable stents were used in 190 of the 233 patients (81.5%) assigned to intraarterial treatment. The adjusted common odds ratio was 1.67 (95% confidence interval [CI], 1.21 to 2.30). There was an absolute difference of 13.5 percentage points (95% CI, 5.9 to 21.2) in the rate of functional independence (modified Rankin score, 0 to 2) in favor of the intervention (32.6% vs. 19.1%). There were no significant differences in mortality or the occurrence of symptomatic intracerebral hemorrhage.

CONCLUSIONS

In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, intraarterial treatment administered within 6 hours after stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current Controlled Trials number, ISRCTN10888758.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Dippel at the Department of Neurology H643, Erasmus MC University Medical Center, PO Box 2040, Rotterdam 3000 CA, the Netherlands, or at d.dippel@erasmusmc.nl.

Dr. Berkhemer, Fransen, and Beumer and Drs. van Zwam, Roos, van der Lugt, van Oostenbrugge, Majoor, and Dippel contributed equally to this article.

*A complete list of investigators in the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on December 17, 2014, and updated on January 1, 2015, at NEJM.org.

N Engl J Med 2015;372:23-30.
DOI: 10.1056/NEJMoa1411587
Copyright © 2014 Massachusetts Medical Society.

JOURNAL OF MEDICINE

ORIGINAL ARTICLE

thin 8 Hours after an Ischemic Stroke

C. de Miquel, C.A. Molina, A. Rovira, Ribó, M. Millán, X. Urrea, P. Cardona, Estañol, J. Blasco, L. Aja, L. Dorado, Z. Pérez, M. Goyal, A.M. Demchuk, for the REVASCAT Trial Investigators*

CT

thrombectomy for the treatment of -based stroke reperfusion registry.

ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

d Assessment of Rapid Treatment of Ischemic Stroke

M. Menon, M. Eesa, J.L. Rempel, J. Thornton, D. Roy, Salpicota, D. Dowlatshahi, D.F. Frei, N.R. Kamal, J. Ryckborszt, F.L. Silver, A. Shuaib, D. Tamplier, W. Baxter, P.A. Burns, H. Choe, J.-H. Heo, M. Kelly, G. Linarez, J.L. Mandzia, J. Shankar, S.P. Scutts, E.E. Smith, W.F. Morrison, S.B. Coats, J.H. Wong, M.W. Lowerison, for the ESCAPE Trial Investigators*

STRACT

exclusion in the anterior circulation, 60 to 80% the onset or do not regain functional independence after rapid endovascular treatment in addition to ischemic stroke with a small infarct core, a moderate-to-good collateral circulation.

ctomy after Intravenous one in Stroke

M.D. Alain Bonafe, M.D., M.D., David J. Cohen, M.D., David, M.D., Tudor G. Jovic, M.D., I.D., Achian H. Sidiqui, M.D., Ph.D., D. Thomas G. Devlie, M.D., Ph.D., Richard du Mesnil de Rochemont, M.D., or the SWIFT PRIME Investigators*

STRACT

therapy for Ischemic Stroke on-Imaging Selection

J. Kleindl, H.M. Dewey, L. Chauvel, N. Yassal, Parsons, T.J. Osofsky, T.Y. Wu, M. Brooks, R. Scroop, P.A. Barber, B. McGuiness, R.V. Clandier, C.F. Bladin, M. Baeve, H. Ricci, G.A. Donnan, and S.M. Davis, NDIA Investigators*

STRACT


occlusions in the proximal anterior circulation when a functional independence when previous tPA, increases reperfus

emic stroke have produced variable outcomes.


more advanced imaging and interventions to improve outcomes.

min.



MR CLEAN
ESCAPE
EXTEND-IA
SWIFT PRIME
REVASCAT
THRACE
THERAPY



RCT récents



RCT récents



tional independence (modified Rankin scale).
vention group than in the control group.

18.4% and 15.5%, respectively ($P=0.60$). Registry data indicated that only patients who met the eligibility criteria were treated outside the trial at participating hospitals.

CONCLUSIONS


Among patients with anterior circulation stroke who could be treated within 8 hours after symptom onset, stent retriever thrombectomy reduced the severity of stroke disability and increased the rate of functional independence. (Funding: Fundació Ictus Malaltia Vascular through an unrestricted grant from Covidien and others; REVASCAT ClinicalTrials.gov number, NCT01692379.)

N ENGL J MED NEJM.ORG


The New England Journal of Medicine

Downloaded from nejm.org by OLIVER NAGGARA on April 23, 2015. For personal use only.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

Traitement IV + IA
Anesthésie locale



TICI 3 à 2H30
mRs 0 à 3 mois




L'IRM a t'elle été indispensable pour
cette thrombectomie ?

L'IRM a t'elle été indispensable pour
cette thrombectomie ?

NON !

Ni pour poser l'indication
Ni pour aider à sa réalisation

	MR CLEAN	REVASCAT	ESCAPE	SWIFT-PRIME	EXTEND-IA
N	500 (16 centres)	206 (4 centres)	316 (22 centres)	196 (39 centres)	70 (14 centres)
Age	≥18	18-85	≥18	18-80	≥18
Img	TDM (IRM)	TDM (IRM)	TDM	TDM (IRM)	TDM
Occl.	ACI, M1, M2	ACI, M1 (M2) ASPECTS>6/5	ACI, M1, M2 ASPECTS>6 Collat.> 50%	ACI, M1 ASPECTS >5 (Mismatch perf)	ACI, M1, M2 Small core perf Mismatch perf
TTT	IA+BMT vs BMT (6h)	IA+BMT vs BMT (8h)	IA+BMT vs BMT (12h)	IV+IA vs IV	IV+IA vs IV
%TIV	87%/91%	68%/78%	73%/79%	100%/100%	100%/100%
DST/ R	IA : 4h20/ 5h32 IV : 1h27	IA: 4h29/ 5h55 IV: 1h15	IA : 2h57/ 4h01 IV : 1h50	IA : 3h44/ ≥4h12 IV : 1h53	IA : 3h30/ 4h08 IV : 2h07
AG	38%	7%	9%	37%	36%
Reprf/ Recan	IA+BMT : 59 % BMT(H24): 33%	IA+BMT:66% BMT:?	IA+BMT: 72% BMT(H24):31%	IV+IA(H27):88% IV (H27): 40%	IV+IA : 86% IV (H24) : 43%
mRs ≤2	IA+BMT=33 % BMT=19% OR aj = 2.2 NNT = 7	IA+BMT=44% BMT=28% OR aj = 2.1 NNT = 6	IA+BMT=53% BMT=29% OR naj = 2.6 NNT = 4	IV+IA=60% IV=35 % OR naj = 2,8 NNT = 4	IV+IA=71 % IV=40 % OR aj = 4.2 NNT = 3



mRS ≤ 2 : Bénéfice absolu 17%; NNT=5,9 (4,5-8,3)

Chirurgie des sténoses carotides symptomatiques $>70\%$, NNT=6

2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment

A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association


Recommandations en imagerie

Imaging

1. Emergency imaging of the brain is recommended before any specific treatment for acute stroke is initiated (*Class I; Level of Evidence A*). In most instances, **nonenhanced CT** will provide the necessary information to make decisions about emergency management. (Unchanged from the 2013 guideline)
2. If endovascular therapy is contemplated, a noninvasive **intracranial vascular study** is strongly **recommended** during the initial imaging evaluation of the acute stroke patient but should not delay intravenous r-tPA if indicated. For patients who qualify for intravenous r-tPA according to guidelines from professional medical societies, initiating intravenous r-tPA before noninvasive vascular imaging is recommended for patients who have not had noninvasive vascular imaging as part of their initial imaging assessment for stroke. Noninvasive intracranial vascular imaging should then be obtained as quickly as possible (*Class I; Level of Evidence A*). (New recommendation)

Recommandations thérapeutiques


- La TM est recommandée à la phase aiguë dans le traitement de l'AVC jusqu'à 6 heures après le début des symptômes chez les patients qui présentent une occlusion proximale des artères cérébrales (carotide, cérébrale moyenne, tronc basilaire). (Grade A, Niveau 1a)
- La TM est réalisée en complément de la TIV lorsqu'elle est indiquée (4h30) ou d'emblée en cas de contre-indications à la TIV. (Grade A, Niveau 1a)



Recommandations thérapeutiques


Recommandations thérapeutiques

- La décision de réaliser une TM **ne doit pas retarder** la réalisation de la TIV. De même, la réalisation de la TIV ne doit pas retarder la TM (Grade A, Niveau 1a).
- La TM doit être réalisée **le plus rapidement possible** dès que son indication a été posée. (Grade A, Niveau 1a)
- La TM doit être réalisée avec des **stents retrievers** approuvés par les autorités de santé. (Grade A, Niveau 1a)



Recommandations sélection des patients

- L'occlusion vasculaire doit être diagnostiquée par une méthode non invasive en première intention avant d'envisager la phase thérapeutique par thrombectomie mécanique. (Grade A, Niveau 1a)
- L'âge élevé (> 80 ans) n'est pas à lui seul une contre-indication à la thrombectomie mécanique. (Grade A, Niveau 1a)



Ça tombe bien
L'IRM n'est pas réalisable dans le
cadre de l'AVC hyper aigu



Pas assez rapide
Appareil non disponible, surchargé
Nombreuses contre-indications
Patients agités (négligents +++)




Stroke

Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled Trial


BK Menon et al. Circulation 2016

- 1% / 4 min.



Pourtant ... Etat des lieux aux US

- 624.000 patients
- IRM ↗
 - 1999 : 28% IRM
 - 2008 : 66% IRM
 - Variations géographiques
- Scanner stable
- Pas de substitution




Hospital availability of MRI

Year	% of Hospitals with MRI access	% of Stroke Patients at Hospital with MRI access
1999	74%	89%
2000	77%	91%
2001	80%	93%
2002	83%	94%
2003	82%	94%
2004	83%	94%
2005	86%	95%
2006	83%	94%
2007	84%	94%
2008	87%	96%

Burke et al. Ann Neurol, 2012

Wide variation and rising utilization of stroke magnetic resonance imaging: data from 11 states

Pas de substitution



For patients with
NIHSS ≥ 6 :
**Anterior
Circulation**
LSW < 6 hrs



Mais...

DWI

NCCT

DWI volume <70cc (anterior)?
Sparing of thalamus, pons or midbrain (posterior)?

Cerebral hemorrhage?

No

Yes

Yes

No

Medical/Surgical
Management

TOF MRA

CTA

Large vessel occlusion (LVO)?

Large Vessel Occlusion (LVO)?

No

Yes

No

Yes

GRE

Significant hemorrhage?


Yes

No

Endovascular Therapy




Le respect des délais “recommandés” peut permettre la réalisation d'une IRM




http://www.ninds.nih.gov/news_and_events/proceedings/stroke_proceedings/recs-acute.htm / AHA 2013

Le respect des délais “recommandés” peut permettre la réalisation d'une IRM





http://www.ninds.nih.gov/news_and_events/proceedings/stroke_proceedings/recs-acute.htm / AHA 2013

Repérage



Mais

1. Recherche de CI
2. Calibration et Pré-scanning par séquence



INDICATIONS:

Déficit moteur de l'hémicorps droit. Mutisme. Début déficit ce jour à 7h50. IRM débuté à 9h13. Suspicion d'accident ischémique aigu. Score NIHSS avant l'irm = 15.

Fin de l'irm à 9h26

TECHNIQUE:

Acquisition de coupes sagittales T1, axiales flair, diffusion, angio-IRM trois D tof du polygone de Willis, séquences axiales T2*, séquence de perfusion.

RÉSULTATS:

Présence d'un hypersignal intra parenchyme sur met en diffusion visible dans la région frontale interne gauche (territoires cérébrale antérieure ainsi que de la région centrale (gyrus pré et post-central gauche) s'étendant plus au cortex insulaire.

Minime hypersignal intra-parenchymateux FLAIR correspondant.

Pas de lésion ischémique controlatérale ou infra-tentoriel.

Hypersignaux FLAIR témoignant d'un ralentissement du flux artériel dans le territoire cérébral antérieur.

Branche insulaire gauche ainsi que sur la ligne médiane (thrombus au sein d'une artère cérébrale antérieure).


Pas d'anomalie signal des sinus veineux. Pas de stigmate hémorragique intra-parenchymateux.

ARM: aspect d'occlusion environ un centimètre de l'origine de A2 gauche ainsi que d'une branche frontale.

d'occlusion des artères carotides. Dilatation infundibulaire de l'origine de l'artère communicante postérieure.

Séquence de perfusion: Aspect d'hypoperfusion dans le territoire de l'artère cérébrale antérieure et le territoire de l'artère basilaire.

plus étendue que les anomalies de diffusion. En particulier, les zones paraissant hypoperfusées mais



Centre hospitalier
Sainte-Anne



En pratique : 90% patients depuis 2003

IRM et AVC : faisabilité ?

Entrée dans l'IRM
→ Début IVT
30 minutes

Tisserand et al Impact of Recanalization Above 70 mL DWI Volume				
	Whole Sample, n=267	DWI<70 mL, n=213	DWI≥70 mL, n=54	P Value
DWI _{baseline} volume, mL	21.6 [9.6–60.1]	15.8 [7.5–55.5]	118.3 [94.8–178.4]	<0.0001
Age, y	71 [59–75]	71 [58–82]	70 [60–79]	0.74
Medical history				
Hypertension, n (%)*	150 (57)	123 (58)	27 (50)	0.29
Diabetes mellitus, n (%)*	36 (14)	29 (14)	7 (13)	1
Hyperlipidemia, n (%)*	98 (37)	79 (37)	19 (35)	0.88
Smoking, n (%)†	107 (40)	88 (42)	19 (35)	0.44
TIA, n (%)*	16 (6)	14 (7)	2 (4)	0.54
Stroke, n (%)*	19 (7)	15 (7)	4 (7)	1
Atrial fibrillation, n (%)†	71 (27)	57 (27)	14 (26)	1
Clinical measure				
Blood glucose, mmol/L†	6.4 [5.4–7.5]	6.3 [5.4–7.3]	6.7 [5.8–8.2]	0.08
Diastolic blood pressure, mm Hg†	80 [70–92]	80 [70–92]	81 [70–92]	0.86
Systolic blood pressure, mm Hg†	150 [132–169]	150 [130–166]	149 [133–169]	0.98
Baseline NIHSS	15 [9–20]	13 [8–18]	19 [15–22]	<0.0001
24-h NIHSS	11 [4–18]	8 [3–17]	16 [11–22]	<0.0001
Etiology				
Large-artery atherosclerosis, n (%)†	41 (15)	34 (16)	7 (13)	0.68
Small-vessel occlusion, n (%)†	0	0	0	
Cardioembolism, n (%)†	138 (53)	113 (54)	25 (47)	0.36
Other determined, n (%)†	14 (5)	12 (6)	2 (4)	0.74
Undetermined, n (%)†	67 (26)	50 (24)	17 (32)	0.29
Time to MRI, min	116 [86–151]	113 [85–148]	130 [90–173]	0.05
Time to IVT, min	152 [120–185]	150 [120–180]	168 [134–202]	0.02

IRM et AVC : faisabilité ?

- Protocole encore plus rapide (8 min → 6 min)
 - Acquisition EPI



Six-Minute Magnetic Resonance Imaging Protocol for Evaluation of Acute Ischemic Stroke Pushing the Boundaries

Kambiz Nael, MD; Rihan Khan, MD; Gagandeep Choudhary, MD; Arash Meshksar, MD;
Pablo Villablanca, MD; Jennifer Tay, MD; Kendra Drake, MD; Bruce M. Coull, MD;
Chelsea S. Kidwell, MD

Background and Purpose—If magnetic resonance imaging (MRI) is to compete with computed tomography for evaluation of patients with acute ischemic stroke, there is a need for further improvements in acquisition speed.

Methods—Inclusion criteria for this prospective, single institutional study were symptoms of acute ischemic stroke within 24 hours onset, National Institutes of Health Stroke Scale ≥ 3 , and absence of MRI contraindications. A combination of echo-planar imaging (EPI) and a parallel acquisition technique were used on a 3T magnetic resonance (MR) scanner to accelerate the acquisition time. Image analysis was performed independently by 2 neuroradiologists.

Results—A total of 62 patients met inclusion criteria. A repeat MRI scan was performed in 22 patients resulting in a total of 84 MRIs available for analysis. Diagnostic image quality was achieved in 100% of diffusion-weighted imaging, 100% EPI-fluid attenuation inversion recovery imaging, 98% EPI-gradient recalled echo, 90% neck MR angiography and 96% of brain MR angiography, and 94% of dynamic susceptibility contrast perfusion scans with interobserver agreements (k) ranging from 0.64 to 0.84. Fifty-nine patients (95%) had acute infarction. There was good interobserver agreement for EPI-fluid attenuation inversion recovery imaging findings ($k=0.78$; 95% confidence interval, 0.66–0.87) and for detection of mismatch classification using dynamic susceptibility contrast-Tmax ($k=0.92$; 95% confidence interval, 0.87–0.94). Thirteen acute intracranial hemorrhages were detected on EPI-gradient recalled echo by both observers. A total of 68 and 72 segmental arterial stenoses were detected on contrast-enhanced MR angiography of the neck and brain with $k=0.93$, 95% confidence interval, 0.84 to 0.96 and 0.87, 95% confidence interval, 0.80 to 0.90, respectively.

Conclusions—A 6-minute multimodal MR protocol with good diagnostic quality is feasible for the evaluation of patients with acute ischemic stroke and can result in significant reduction in scan time rivaling that of the multimodal computed tomographic protocol. (*Stroke*. 2014;45:1985–1991.)

Key Words: magnetic resonance angiography ■ magnetic resonance imaging ■ perfusion imaging ■ stroke

IRM et AVC : faisabilité ?





Table 1. MR Imaging Protocol and Sequence Parameters


	DWI	EPI-FLAIR	EPI-GRE	CE-MRA	DSC
TR/TE, ms	4600/65	100 00/82	1860/48	3.3/1.2	1450/22
FA, °	90	90	90	25	90
Matrix, mm	160	128	192	448	128
FOV, mm	220	220	220	340	220
Slices (n×thickness), mm	30×4	30×4	40×3	120×0.8	30×4
GRAPPA	3	3	3	4	3
Acquisition time, s	58	52	56	22	90

CE-MRA indicates contrast-enhanced magnetic resonance angiography; DSC, dynamic susceptibility contrast perfusion; DWI, diffusion-weighted imaging; EPI, echo-planar imaging; FA, flip angle; FLAIR, fluid attenuation inversion recovery imaging; FOV, field-of-view; GRAPPA, generalized autocalibrating partially parallel acquisition; GRE, gradient recalled echo; MR, magnetic resonance; TE, echo-time; Tmax, time-to-maximum; and TR, repetition time.

IRM et AVC : faisabilité ?





Patiante de 90 ans
NIHSS = 8
Onset to MRI= 70'




IRM et AVC : faisabilité ?

Acquisition EPI




15 sec




FLAIR

EPI-FLAIR






ARM




T2*< 10 sec

Patient agité < 5 min






T2* classique




FLAIR

Attention : DWI et FLAIR se ressemblent !!!!




Diffusion



FLAIR



b0



T2*

ECHO PLANAR

IRM et AVC : faisabilité ?

- Protocole rapide → Ne pas retarder le traitement
 - « door to needle time »
 - IRM vs TDM = 87 / 68 minutes (médiane)[1]
 - Outcome équivalent
 - 25% DTNT <60'

MRI Screening Before Standard Tissue Plasminogen Activator Therapy Is Feasible and Safe

Dong-Wha Kang, MD, PhD; Julio A. Chalela, MD; William Dunn, MD; Steven Warach, MD, PhD;
NIH-Suburban Stroke Center Investigators

Background and Purpose—MRI screening for thrombolytic therapy may improve patient selection. Alternatively, it may excessively delay treatment and thereby lead to worse outcomes. We hypothesized that times to treatment and outcomes in a stroke center with immediate MRI access and interpretation would not differ from those of the typical clinical practice.

Methods—We compared the results of 120 consecutive patients treated with intravenous tissue plasminogen activator (tPA) within 3 hours of onset at our center with those of the 2 largest multicenter registries of tPA use.^{5,6} In addition to standard criteria, MRI specific eligibility criteria were applied in 97 patients. MRI was not performed in 23 patients because of contraindications to MRI or late patient arrival (>2.5 hours). Outcomes were the modified Rankin Scale (mRS) obtained at 3 months.

Results—Times to treatment (median door-to-needle time 81.5 minutes; median onset-to-needle time 135 minutes) and outcomes (mRS 0 to 1, 40.8%; mRS 0 to 2, 47.5%) were not inferior to those of the typical clinical practice. Door-to-needle time was shorter in computed tomography (CT) screening (67.5 ± 22.5 minutes; n=23) than in MRI screening (86.8 ± 21.5 minutes; n=97; $P < 0.001$). However, outcomes were not different between MRI screening (mRS 0 to 1, 42.3%; mRS 0 to 2, 49.5%) and CT screening (mRS 0 to 1, 34.8%; mRS 0 to 2, 39.1%). Neither times to treatment nor MRI screening was predictive of outcomes.

Conclusion—These data demonstrate that MRI screening before tPA therapy is feasible and not associated with unacceptable times to treatment or outcomes. (*Stroke*. 2005;36:1939-1943.)

[1] Kang DW et al. *Stroke* 2005

DTNT < 60 min et IRM : faisabilité ?

Table 2 Changes in SMART metrics with the QI process


Characteristic	1st half of 2012	2nd half of 2012	1st half of 2013	2nd half of 2013	p Value
No. of patients treated with IV tPA (% of patients evaluated)	23 (9)	27 (12.2)	46 (16.0)	39 (12.8)	0.11
Patients with DTN time ≤60 min, %	13.0	11.1	28.2	61.5	0.00001 ^a
Door-to-stroke team paging time, min ^b	6 (3-18)	12 (7-21.5)	6 (5-11)	3 (0-8.5)	0.001 ^a
Door-to-MRI start time, min ^b	49 (39-61.5)	52 (40.5-60)	44 (31.2-57)	24 (16.5-37)	<0.0001 ^a
MRI-to-needle time, min ^b	40 (29.5-52.5)	31 (23.5-39)	33.5 (21.7-40.7)	30.5 (25-38)	0.13
Door-to-needle time, min ^b	93 (77-103)	82 (71-92.5)	71 (58-92)	55 (46.5-76.5)	<0.0001 ^a
Last seen normal-to-needle time, min ^b	166 (150-195.5)	160 (114-219)	141.5 (109.7-191.7)	140 (96-201)	0.18

Abbreviations: DTN = door-to-needle; QI = quality improvement; SMART = Screening with MRI for Accurate and Rapid Stroke Treatment; tPA = tissue plasminogen activator.

^a Statistically significant.


^b Reported as median (interquartile ratio 25-75).

IRM en 1^{ère} intention: pourquoi tant d'efforts ?




Éliminer une hémorragie

< 1 min




SIZE OF TREATMENT EFFECT		
LEVEL I Data derived from multiple randomized clinical trials or meta-analyses	CLASSE Ia Benefit >> Risk Additional studies with increased effectiveness needed. If no additional trials to perform, treatment becomes definitive treatment.	CLASSE IIa Benefit > Risk Additional studies with benefit/side effect ratio needed. If no additional trials to perform, treatment becomes definitive treatment.
LEVEL II Limited preexisting evidence? Data derived from a single randomized trial or observational studies	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Only expert opinion, case studies, or observation of cases 	<ul style="list-style-type: none"> Recommendation in favor of treatment or procedure testing useful/effective Greater conflicting evidence from single randomized trial or observational studies
LEVEL III Very limited preexisting evidence? Only consensus opinion of experts, case studies, or animal studies	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Only expert opinion, case studies, or observation of cases 	<ul style="list-style-type: none"> Recommendation in favor of treatment or procedure testing useful/effective Greater conflicting evidence from single randomized trial or observational studies
		<ul style="list-style-type: none"> Recommendation that procedure or treatment is not useful/effective and may be harmful Only expert opinion, case studies, or observation of cases

Kidwell et al. JAMA. 2004 Fiebach et al. Stroke 2004
 Silvera et al. AJNR 2005 Oppenheim et al. Cerebrovasc Dis. 2005;
 Brazelli et al. BMJ, 2009 . Copenhaver Neurology 2009



Excellent reproductibilité !

Confirmer l'ischémie







SIZE OF TREATMENT EFFECT			
LEVEL I Data derived from multiple randomized controlled trials or meta-analysis	LEVEL II Data derived from multiple observational studies or meta-analyses	LEVEL III Additional studies with direct comparison between interventions that would help inform treatment	LEVEL IV Non-randomized studies, case reports, case series, or anecdotes
<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective Recommendation that procedure or treatment is useful/effective based on evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective based on evidence from multiple randomized trials or meta-analyses Recommendation that procedure or treatment is useful/effective based on evidence from multiple observational studies or meta-analyses 	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective based on evidence from multiple observational studies or meta-analyses Recommendation that procedure or treatment is useful/effective based on evidence from single observational studies or meta-analyses 	<ul style="list-style-type: none"> Recommendation that procedure or treatment is useful/effective based on evidence from single observational studies or meta-analyses Recommendation that procedure or treatment is useful/effective based on evidence from observational studies or anecdotes
LEVEL I Multiple populations evaluated Data derived from multiple randomized controlled trials or meta-analyses	LEVEL II Limited populations evaluated Data derived from a single randomized trial or meta-analysis	LEVEL III Additional studies with direct comparison between interventions that would help inform treatment	LEVEL IV Non-randomized studies, case reports, case series, or anecdotes
ESTIMATE OF CERTAIN EFFECTIVENESS OF TREATMENT/EFFECT			
Recommendation that procedure or treatment is useful/effective			
Recommendation that procedure or treatment is useful/effective based on evidence from multiple randomized trials or meta-analyses			
Recommendation that procedure or treatment is useful/effective based on evidence from multiple observational studies or meta-analyses			
Recommendation that procedure or treatment is useful/effective based on evidence from single observational studies or meta-analyses			
Recommendation that procedure or treatment is useful/effective based on evidence from observational studies or anecdotes			

1. Brazelli et al. BMJ 2009
2. Schellinger et al. Neurology 2010








Stroke mimics

Cas 1




Ischemie

Cas 2







Migraine



- 512 patients traités sur scanner
- 14% stroke mimics !

Chernyshev, et al. Neurology 2010

Étiologie



Braemswig et al.
Stroke 2013

IRM en 1^{ère} intention: pourquoi tant d'efforts ?

- 80-85% patients [1-5], Sainte Anne 90%
- Diminue la mortalité et augmente les patients mRs ≤1 [6, 7]
- Meilleure sélection
- Rapport coût-efficacité positif [7]

Lancet Neurol 2006; 5: 661–67	CT-based (n=209)	MRI-based (all) (n=173)	p
sICH	19 (9%)	5 (3%)	0·01†
Favourable outcome at 90 days	79 (38%)	63 (36%)	0·78†
Independence at 90 days	100 (48%)	91 (53%)	0·35†
Death at 90 days	44 (21%)	21 (12%)	0·021†

*Kruskal-Wallis test; † Pearson's χ^2 test. Results can be more than 100% due to rounding

Table 3: Comparison of main safety and outcome events between CT-based and MRI-based treated patients


Pourquoi tant d'efforts ?


10% de patients AVC ont un traitement de recanalisation

L'IRM en 1^{ère} intention peut permettre d'augmenter ce %

L'IRM permet de dater

- 16-28% des AVC d'horaire inconnus
- Des patients bénéficient de la recanalisation
- Mismatch FLAIR-Diffusion
- RCT en cours [9, 10]





> 4h30

Délai post occlusion


L'IRM est indispensable

1. Petkova et al. Radiology 2011.

2. Thomalla et al. Lancet Neurol 2011.


IRM en 1^{ère} intention, c'est

- Définir simplement le volume de l'infarctus
- Définir la pénombre ischémique - la collatéralité
- Visualiser le thrombus



Volume de l'infarctus

- Information directe en DWI
- Indirecte en CT Perfusion
 - Sous estimée en CBV
 - Meilleur en CBF
- Faible rapport S/B et C/B sur les cartes de CT Perfusion*
- DWI volume > 70 mL correspond à un volume en CT-CBF de 10.7 ... à 124.1 mL





* "Depends on collateral circulation, contrast amount, cardiac output, quality and intensity of the x-ray beam, CTP reconstruction algorithm"

Schaefer P et al. Stroke 2015

Volume de l'infarctus cérébral avant traitement : intérêt ?

- Prédicatif de la réponse au traitement
 - “Target” mismatch (< 70 mL)
 - Complications précoces
 - Transformation hémorragique >100 mL
 - Oedème “malin” : > 145 mL
 - Pronostic à 3 mois

Avant traitement



T. hémorragique

Oedème malin

1. Parsons et al. J Cereb Blood Flow Metab. 2010; 2. Mlynash et al. Stroke 2011; 3. Davis et al. Lancet Neurol 2008; 4. Lansberg et al. Lancet Neurol 2012; 5. Oppenheim et al. Stroke 2000

2. Olivot et al. Stroke 2009. Takasawa et al. Stroke 2008;

3. Christensen et al. Stroke 2010; Lansberg et al. Lancet Neurol 2012


Volume de l'infarctus cérébral

*Exclusion criteria**



DWI > 1/3 ACM

Volume_{DWI} ABC/2 > 100 mL

ASPECTS < 7, < 6 en IRM (ou CT)



Sims et al. Neurology. 2009



DWI-ASPECTS=4

* <https://clinicaltrials.gov/>

Peut-on évaluer simplement en routine clinique le Volume de l'infarctus cérébral ?

Can DWI-ASPECTS Substitute for Lesion Volume in Acute Stroke?

Constance de Margerie-Mellon, MD*; Guillaume Turc, MD*; Marie Tisserand, MD;
Olivier Naggara, PhD; David Calvet, PhD; Laurence Legrand, MD; Jean-François Meder, PhD;
Jean-Louis Mas, MD; Jean-Claude Baron, ScD; Catherine Oppenheim, PhD


Background and Purpose—The extent of diffusion lesion on pretreatment imaging is a risk factor for poor outcome and hemorrhagic transformation after thrombolysis, and volumes of 70 to 100 mL have been advocated as cutoffs. However, estimating diffusion-weighted imaging (DWI) lesion volume (Vol_{DWI}) in the acute setting may be cumbersome. We aimed to determine whether the DWI-Alberta Stroke Program Early CT Score (DWI-ASPECTS) can substitute for Vol_{DWI} .


Methods—DWI-ASPECTS and Vol_{DWI} were measured retrospectively on pretreatment MRI (median onset-to-MRI delay=122 minutes) in 330 consecutively treated patients with middle cerebral artery stroke.

Results—DWI-ASPECTS and Vol_{DWI} were strongly correlated ($\rho=-0.82$), but each DWI-ASPECTS point corresponded to a wide range of Vol_{DWI} . All patients with DWI-ASPECTS ≥ 7 ($n=207$) had $\text{Vol}_{\text{DWI}} < 70$ mL, whereas 32 of the 34 patients with DWI-ASPECTS < 4 had $\text{Vol}_{\text{DWI}} > 100$ mL. However, intermediate DWI-ASPECTS (4–6; $n=89$) corresponded to highly variable Vol_{DWI} (median, 66 mL; interquartile range, 40–98).

Conclusions—Although each DWI-ASPECTS point corresponds to a wide range of volumes, DWI-ASPECTS < 4 or ≥ 7 may be used as reliable surrogates of $\text{Vol}_{\text{DWI}} > 100$ or < 70 mL, respectively. (*Stroke*. 2013;44:3565–3567.)

Key Words: ASPECTS ■ diffusion-weighted imaging ■ stroke ■ thrombolytic therapy






DWI-ASPECTS $< 4 = \text{vol} > 100 \text{ mL}$
 DWI-ASPECTS $\geq 7 = \text{vol} < 70 \text{ mL}$


1. De Margerie et al. Stroke. 2013
2. Schröder et al. Stroke 2014

DWI-ASPECTS

Élargir la fenêtre thérapeutique > 6H



PWI Tmax > 6s



DWI



TARGET MISMATCH (DEFUSE 2)

$$\frac{\text{Vol}_{\text{PWI}} (\text{Tmax} > 6\text{s})}{\text{Vol}_{\text{DWI}}} \geq 1.8$$


and

$$\text{Vol}_{\text{DWI}} < 70 \text{ mL}$$

and

$$\text{PWI} (\text{Tmax} > 10\text{s}) < 100 \text{ mL}$$


Exclusion of
Large core



>70 mL



>145 mL





Olivet et al. Stroke 2009. Takasawa et al. Stroke 2008;
Christensen et al. Stroke 2010; Lansberg et al. Lancet Neurol 2012

Parsons et al. J Cereb Blood Flow Metab. 2010. Mlynash et al. Stroke 2011. Davis et al. Lancet Neurol 2008.
Oppenheim et al. Stroke 2000

IRM en 1^{ère} intention, c'est

- Définir simplement le volume de l'infarctus
- Définir la pénombre ischémique - la collatéralité
- Bilan vasculaire






- Penombre jusqu'a 24-hrs¹⁻³
- Penombre sauvée → meilleur outcome ⁴⁻⁷

- > 6h ?
- Sans heure de début (réveil) ?


1. Marchal et al. 1996. Darby et al 1999; 2. Heiss et al 1992; 3. Markus et al; 2004

4. Lansberg et al. 2012; 5. Ma et al 2014; 6. Davis 2008; 7. Friedrich et al 2014 ...



Tmax + 6s DSC*
 $< 20 \text{ mL}/100\text{g}/\text{min}$

H 75 ans,
 Déficit moteur
 gauche
 survenu il y a
 5h30




Suivi
 (non recanalisation)

Objectif :
 élargir la fenêtre de
 thrombolyse $> 6\text{h}$





* Zaro-Weber et al., Olivot et al. 2009; Takasawa et al. 2008.

Marqueurs de pénombre ischémique

Les « mismatch »




H 75 ans,
Déficit survenu
il y a 5h30




Tmax

DSC*
 $< 20 \text{ mL}/100\text{g}/\text{min}$


VSC




Tmax + 2s




+ 4s



+ 6s



Suivi




Objectif : Élargir la fenêtre thérapeutique

* Zaro-Weber et al., Olivot et al. 2009; Takasawa et al. 2008.

PWI Tmax > 6s

DWI



TARGET MISMATCH (DEFUSE 2)

$$\frac{\text{Vol}_{\text{PWI}} (\text{Tmax} > 6\text{s})}{\text{Vol}_{\text{DWI}}} \geq 1.8$$


and

$$\text{Vol}_{\text{DWI}} < 70 \text{ mL}$$


and

$$\text{PWI} (\text{Tmax} > 10\text{s}) < 100 \text{ mL}$$

A. Target Mismatch Population




B. No Target Mismatch Population




H + 3.5


NIHSS=17




NIHSS=17



Dans la vraie vie ?



MR RESCUE : Software failure: 42% patients




Kidwell et al. NEJM. 2013

Kidwell et al. Stroke 2013

Usability
Accuracy
Speed
Affordability
GA (portability)
Credibility

Churilov et al.
Int J Stroke 2013

+ manual interface
in case of failure !




PWI/DWI=1


A few examples ...



OLEA sphere




GE Healthcare "prototype"




RAPID




AVANT TRAITEMENT



24 hrs après recanalisation




FLAIR vascular hyperintensities la perfusion du pauvre ?




Sanossian, AJNR, 2009 Azizyan, AJNR, 2011

Mismatch FVH-DWI


Aphasicie brutale chez un patient de 67 ans (NIHSS=5)






→ Association avec le mismatch PWI-DWI (Sen=92%)



Mismatch FVH-DWI +




Mismatch FVH-DWI -




Association

- recanalisation (ARM à 24h)
- évolution clinique favorable (mRS à 3 mois ≤2)

IRM initiale (86 min)




IRM à H24



mRS à 3 mois = 0

FLAIR vascular hyperintensities la perfusion du pauvre ?

- Association entre recanalisation et évolution clinique favorable à 3 mois significative chez les patients avec mismatch FVH-DWI (OR de 16.2)
- Non significative chez les patients sans mismatch FVH-DWI



Mismatch FVH-DWI -

Fluid-Attenuated Inversion Recovery Vascular Hyperintensities–Diffusion-Weighted Imaging Mismatch Identifies Acute Stroke Patients Most Likely to Benefit From Recanalization

Laurence Legrand, MD; Marie Tisserand, PhD*; Guillaume Turc, PhD*; Myriam Edjlali, MD; David Calvet, PhD; Denis Trystram, MD; Pauline Roca, PhD; Olivier Nagara, PhD; Jean-Louis Mas, MD; Jean-Francois Méder, PhD; Jean-Claude Baron, ScD; Catherine Oppenheim, PhD

Background and Purpose—Fluid-attenuated inversion recovery vascular hyperintensities (F VH) beyond the boundaries of diffusion-weighted imaging (DWI) lesion (F VH-DWI mismatch) have been proposed as an alternative to perfusion-weighted imaging (PWI)-DWI mismatch. We aimed to establish whether F VH-DWI mismatch can identify patients most likely to benefit from recanalization.

Methods—F VH-DWI mismatch was assessed in 164 patients with proximal middle cerebral artery occlusion before intravenous thrombolysis. PWI-DWI mismatch ($PWI_{\text{mismatch}}/\text{DWI} > 1.8$) was assessed in the 104 patients with available PWI data. We tested the associations between 24-hours complete recanalization on magnetic resonance angiography and 3-month favorable outcome (modified Rankin Scale score ≤ 2), stratified on F VH-DWI (or PWI-DWI) status.

Results—F VH-DWI mismatch was present in 121/164 (74%) patients and recanalization in 50/164 (30%) patients. The odds ratio for favorable outcome with recanalization was 16.2 (95% confidence interval, 5.7–46.5; $P < 0.0001$) in patients with F VH-DWI mismatch and 2.6 (95% confidence interval, 0.6–12.1; $P = 0.22$) in those without F VH-DWI mismatch ($P = 0.048$ for interaction). Recanalization was associated with favorable outcome in patients with PWI-DWI mismatch (odds ratios, 9.9; 95% confidence interval, 3.1–31.3; $P = 0.0001$) and in patients without PWI-DWI mismatch (odds ratios, 7.0; 95% confidence interval, 1.1–44.1; $P = 0.047$), $P = 0.76$ for interaction.

Conclusion—The F VH-DWI mismatch may rapidly identify patients with proximal occlusion most likely to benefit from recanalization. (*Stroke*. 2016;47:424–427. DOI: 10.1161/STROKEAHA.115.010999.)

Résultats

Evolution clinique favorable à 3 mois

Mismatch PWI-DWI +

OR_{recanalisation}=9.9
(95%CI, 3.1-31.3; $P<0.0001$)

Mismatch PWI-DWI -



OR_{recanalisation}=7.0
(95%CI, 1.1-44.1; $P=0.047$)

$P=0.76$ (interaction)



Discussion

Mismatch FVH-DWI

- Identifier patients avec occlusion M1 susceptibles de bénéficier de la recanalisation après thrombolyse IV
- Avantages nombreux/mismatch PWI-DWI
 - Pas de gadolinium
 - Pas de post-traitement
 - Gain de temps





Mismatch: que retenir ?



Mismatch: que retenir ?

- Tmax de plus en plus utilisé
- Logiciel de post ttt automatique
 - Hypoperfusion ($T_{max} > 6$ sec)
 - Vol Diffusion
 - Essais randomisés en cours



ECASS 4

- Essai randomisé de phase III
- rt-PA versus placebo
- 4.5-9h ou AVC du réveil
- Inclusion : **MISMATCH**

1) a ratio between the volumes of critically hypoperfused tissue and the ischemic core ≥ 1.8 , with an absolute difference ≥ 15 mL; 2) ischemic core volume < 70 mL and; 3) volume of tissue with a severe delay in bolus arrival ($T_{max} > 10$ sec) < 100 mL.

2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment

A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Imaging


1. Emergency imaging of the brain is recommended before any specific treatment for acute stroke is initiated (*Class I; Level of Evidence A*). In most instances, nonenhanced CT will provide the necessary information to make decisions about emergency management. (Unchanged from the 2013 guideline)
2. If endovascular therapy is contemplated, a non-invasive intracranial vascular study is strongly recommended during the initial imaging evaluation of the acute stroke patient but should not delay intravenous r-tPA if indicated. For patients who qualify for intravenous r-tPA according to guidelines from professional medical societies, initiating intravenous r-tPA before noninvasive vascular imaging is recommended for patients who have not had noninvasive vascular imaging as part of their initial imaging assessment for stroke. Noninvasive intracranial vascular imaging should then be obtained as quickly as possible (*Class I; Level of Evidence A*). (New recommendation)

2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment

A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

The benefits of additional imaging beyond CT and CTA or MRI and MRA such as CT perfusion or diffusion- and perfusion-weighted imaging for selecting patients for endovascular therapy are unknown (*Class IIb; Level of Evidence C*). Further randomized, controlled trials may be helpful to determine whether advanced imaging paradigms using CT perfusion, CTA, and MRI perfusion and diffusion imaging, including measures of infarct core, collateral flow status, and penumbra, are beneficial for selecting patients for acute reperfusion therapy who are within 6 hours of symptom onset and have an ASPECTS <6. Further randomized, controlled trials should be done to determine whether advanced imaging paradigms with CT perfusion, MRI perfusion, CTA, and diffusion imaging, including measures of infarct core, collateral flow status, and penumbra, are beneficial for selecting patients for acute reperfusion therapy who are beyond 6 hours from symptom onset. (New recommendation)

Sélection des patients



- Pas d'imagerie avancée

REVASCAT – MR CLEAN – THRACE –
THERAPY

- Absolute benefit: 13% NTT=7.7 (5.6-12.5)

- Imagerie avancée

– EXTEND IA - SWIFT PRIME – ESCAPE

– Absolute benefit: 25%, NTT=4 (3-5.9)

L'IRM est elle indispensable pour une thrombectomie

- Non

Pas pour l'indication

Pas pour aider à sa réalisation




→ Raisonnement similaire à celui pour la recanalisation IV

- Oui

AVC sans heure de début

Sélection individualisée des patients

Déficit constaté
au réveil.
IRM 5 h plus tard




FLAIR


Diffusion

MTT




Traitements par rtPA Intra Artériel





IRM initiale



Contrôle précoce




sang et diffusion




Ischémie cérébrale en IRM

Angio-RM



>
:





VISUALISATION DU SITE DE L'OCCLUSION
ÉVALUATION DE LA CIRCULATION COLLATERALE
ÉVALUATION DE L'ATTEINTE OU DE LA COMPLEXITÉ ANATOMIQUE DES TSA

Angio-RM


Troncs supra-aortiques

- FACTEUR IMPORTANT conditionnant la durée de la procédure endovasculaire
- Variations
 - >50% origines séparées des TSA
 - 25% origine commune TABC et ACCG
 - 16% ACCG naissant du TABC
 - <3% AV ou ASCD naissant de l'Aorte
 - RARE : right sided AA



Angio-RM


Troncs supra-aortiques




Rationnel recanalisation mécanique

Limites de la Fibrinolyse IV

- **Importance de la taille du thrombus pour la recanalisation**
- Stroke. 2011; PMID: 21474810



Le fibrinolyse IV est quasiment inefficace pour des thrombus $\geq 8\text{mm}$



- Longueur du thrombus aspi vs stent
- Penombre – collatéralité
- Reveil

L'IRM est elle indispensable pour la thrombectomie ?



- **NON ! Certainement pas indispensable**

Time is brain ?

La thrombolyse intraveineuse (IV) dans les 4.5 h est le seul traitement :

- **ayant fait la preuve de son efficacité**
- **autorisé dans l'infarctus cérébral**
- **Le bénéfice clinique de la thrombolyse IV est basé sur la désobstruction artérielle**

Objectif : recanalisation



Alexandrov. *J Int Med* 2010;267:209-19.
Saqqur et al. *Stroke* 2007;38:948-54.

Pluridisciplinarité !

- La thrombectomie mécanique est un traitement en « bout de chaîne »
- Filière fluide
 - Urgences – SAMU – Pompiers
 - Neuroradiologie diagnostic
 - Neurologie vasculaire – UNV
 - Neuro- anesthésiste –réanimateur

RCT futurs

